MedDataX Logo

Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection

NCT ID: NCT03803137

Last Updated: 2020-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-09-20

Study Completion Date

2021-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bronchopulmonary cancer, with 39 000 new cases and 30 000 deaths per year, is a main issue in public health in France. It is the leading cause of cancer death in France. A lot of progress in medical care has been made, but surgery remains the most effective treatment, when it is still possible. The goal is to detect and manage the lung cancer as early as possible. Alongside screening strategies by annual thoracic scanner, new approaches with innovative technologies open up for cancer detection and therapeutic follow-up.

The study of volatile organic compounds (VOC) detected in exhaled air or in sweat, is an innovative research area for respiratory diseases. The volatolomic analysis can be done either by the technique of the mass spectrometry which allows the identification of each VOC in the exhaled air or by the technique of electronic nose, simpler and faster, which provides an idea of the general profile of the VOC without identifying them. The VOC have shown their interest in some situations, such as diagnostic or prognostic tool in patients followed for thoracic tumorous pathology or bronchial or pulmonary vascular diseases.

The composition of VOC in exhaled air and sweat is altered in patients with lung cancer. The VOC analysis and their variation could be used particularly in the follow-up of patients treated for lung cancer.

The purpose of this clinical research is to identify the VOCs related to lung cancers by comparing the VOC profiles in exhaled air and in sweat from patients diagnosed with localized lung cancer before and after resection surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer, Non-small Cell

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

VOC analysis

VOC analysis in exhaled air and sweat in patients with thoracic surgery for carcinological resection

Group Type EXPERIMENTAL

VOC analysis

Intervention Type OTHER

VOC analysis in exhaled air with e-noses and mass spectrometry

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

VOC analysis

VOC analysis in exhaled air with e-noses and mass spectrometry

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient aged ≥ 18 years old
* Patient with non-small cell lung cancer
* Operable grade I or II
* No specific treatment before surgery (radiotherapy, chemotherapy or targeted therapy)
* Patient with healthcare insurance


* Treatment with radiotherapy, chemotherapy, or neoadjuvant cancer targeted therapy before thoracic surgery
* Patient with oxygen therapy or invasive ventilation
* Patient unable to perform a slow vital capacity
* Dermatological therapy interfering with sweat collection (psoriasis, irritant dermatitis, for instance)
* Pregnant women
* Patient deprived of liberty by judicial or administrative decision
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Hopital Foch

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Philippe Devillier

Role: PRINCIPAL_INVESTIGATOR

Pneumology department

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Foch

Suresnes, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Elisabeth Hullier-Ammar

Role: CONTACT

Phone: +33 1 46 25 11 75

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Philippe Devillier

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2017081

Identifier Type: -

Identifier Source: org_study_id